Linked Life Data

3187441

Source:http://linkedlifedata.com/resource/pubmed/id/3187441

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1988-12-19
pubmed:abstractText
Disturbances of calcium homeostasis might be involved in the pathogenesis of the metabolic derangements associated with uraemia. Indices of glucose and lipoprotein metabolism as well as blood pressure were measured in nine patients with chronic renal failure who were on regular hemodialysis. Seven of them thereafter received alpha-calcidol (a synthetic analogue to active vitamin D) intravenously for three months. Prior to therapy the patients had, compared with age and sex matched controls, impaired glucose tolerance, hyperlipoporteinemia and raised blood pressure. Treatment with alpha-calcidol reduced elevated serum levels of parathyroid hormone (PTH). Concomitantly there was a reduction of fasting blood glucose and HbA1C (glycosylated hemoglobin) concentrations and an improvement of the glucose tolerance, whereas insulin concentrations were unaffected. There was a reduction of whole serum triglycerides and an increase of HDL cholesterol. A significant decrease was also observed for systolic blood pressure. This pilot study suggests that treatment with active vitamin D, probably through its effects on calcium metabolism, is beneficial with regard to the metabolic disturbances in uraemia.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0036-5599
pubmed:author
pubmed:issnType
Print
pubmed:volume
22
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
219-22
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
A pilot study of metabolic effects of intravenously given alpha-calcidol in patients with chronic renal failure.
pubmed:affiliation
Department of Internal Medicine, Gävle County Hospital, Uppsala, Sweden.
pubmed:publicationType
Journal Article